Hyperfine, Inc.

HYPR Nasdaq SEC CIK 1833769
Follow Hyperfine Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $6M +73.4% vs same quarter last year
Net income −$6M +45.7% vs same quarter last year
EPS, diluted −$0.06 +57.1% vs same quarter last year
Operating cash flow −$6.1M −9% vs same quarter last year
Revenue by quarter
$2.3M
$2.1M
$2.7M
$3.4M
$5.3M
$3.9M
$3.9M
$6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$80M−$60M−$40M−$20M$0$20MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$13.6M−$35.6M
FY24$12.9M−$40.7M
FY23$11M−$44.2M
FY22$6.8M−$44.2M
FY21$1.5M−$64.9M
FY20$294K−$23.4M
FY19--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−10000%−7500%−5000%−2500%0%2500%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2549.8%−273.4%−262.3%
FY2445.7%−335.3%−315.9%
FY2343.1%−436.1%−401%
FY2213.3%−1084.2%−649.2%
FY21−78%−4336.1%−4335%
FY20−162.2%−7990.1%−7968.4%
FY19---
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$29.1M
FY24−$39.2M
FY23−$42.6M
FY22−$72.9M
FY21−$49.9M
FY20−$23.1M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Hyperfine
  • Healthcare median
−8000%−6000%−4000%−2000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearHyperfineHealthcare median
FY25−262.3%−30.6%
FY24−315.9%−47%
FY23−401%−58%
FY22−649.2%−80.4%
FY21−4335%−71.9%
FY20−7968.4%−62.2%
FY19-−46.3%